# A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

Source: https://onco.cc/trials/nct07266441/  
OnCo record `nct07266441` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of JNJ-79635322 in multiple myeloma, run by Janssen Research & Development, LLC, now recruiting.

## Summary

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma is a phase 2 interventional study registered as NCT07266441 by Janssen Research & Development, LLC, with 157 participants planned, started 2026-02-08 and due to reach its primary completion in 2027-06-14. Interventions recorded: JNJ-79635322. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07266441
- Phase: 2
- Setting: A Phase 2, Open-label Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) Who Have Received at Least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti-CD38 Antibody
- Sponsor: Janssen Research & Development, LLC
- Enrolled: 157

## Sources

- ClinicalTrials.gov NCT07266441: https://clinicaltrials.gov/study/NCT07266441

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [JNJ-79635322](https://onco.cc/drugs/jnj-79635322/)
- companies: [Johnson & Johnson](https://onco.cc/companies/johnson-johnson/)

---
JSON: https://onco.cc/api/v1/entities/nct07266441.json